Ovarian Diseases

26 registered clinical trials studyying Ovarian Diseases — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	A Novel Ovarian Reserve Monitoring Algorithm for Patients at Risk of Ovarian Injury From Gonadotoxic Therapy NCT05048654	University of Colorado, Denver	—
Not Yet Recruiting	A Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gy NCT06828419	Second Affiliated Hospital of Wenzhou Medical University	N/A
Not Yet Recruiting	4K Versus 3D Total Laparoscopic Bilateral Oophorectomy: Tools in Comparison NCT06750003	Azienda Sanitaria-Universitaria Integrata di Udine	N/A
Recruiting	Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian C NCT05753826	Fujian Cancer Hospital	Phase 2
Active Not Recruiting	AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Can NCT05617755	Arsenal Biosciences, Inc.	Phase 1
Unknown	Added Value of O-RADS in Evaluation of Ovarian Lesions NCT04579575	Assiut University	—
Terminated	A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) NCT05001282	Elucida Oncology	Phase 1 / Phase 2
Active Not Recruiting	Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cance NCT04807166	Wenjun Cheng	Phase 2
Recruiting	Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer NCT04519151	Sheba Medical Center	Phase 2
Unknown	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian NCT04556071	Xiaoxiang Chen	Phase 2
Unknown	Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer NCT04566952	Xiaoxiang Chen	Phase 2
Unknown	Turner Syndrome Minipuberty Study NCT04189406	Radboud University Medical Center	—
Completed	Ovarian Reserve and Ankylosing Spondylitis NCT04209881	Kanuni Sultan Suleyman Training and Research Hospital	—
Completed	Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer NCT03562897	Catalysis SL	Phase 2
Completed	Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of M NCT03593681	Boston Scientific Corporation	—
Completed	Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer NCT02973750	H. Lee Moffitt Cancer Center and Research Institute	—
Completed	89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients NCT01832116	University Medical Center Groningen	Phase 1
Completed	Feasability Study of Removing the Ovaries and Fallopian Tubes NCT01566955	Heidelberg University	N/A
Completed	Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients Wit NCT01462890	AGO Study Group	Phase 3
Completed	Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced E NCT01460979	AGO Study Group	Phase 2
Completed	Antral Follicle Priming Prior to ICSI (Intracytoplasmic Sperm Injection) in Previously Diagnosed Low Responder NCT01310647	Instituto de Investigacion Sanitaria La Fe	Phase 2
Terminated	A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ova NCT01016054	Astellas Pharma Inc	Phase 1
Terminated	Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer NCT01292733	Swedish Medical Center	EARLY_Phase 1
Completed	A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer NCT00816764	Astellas Pharma Inc	Phase 1
Completed	A Study of Trabectedin in Patients With Advanced Ovarian Cancer NCT00050414	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2
Completed	Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment NCT00210249	Institut Bergonié	—